Crown Bioscience to present preclinical cancer drug development at AACR conference


Crown Bioscience, will showcase their scientific expertise at American Association for Cancer Research's International Conference (AACR) in Chicago, on April 14 to 18.

Crown Bioscience is a wholly-owned subsidiary of Crown Bioscience International.

"CrownBio's scientists will present more than a dozen scientific posters describing their latest efforts to revolutionise preclinical development of cancer treatments," Crown Bioscience said in a statement.

"These scientific posters will demonstrate the combined power of CrownBio's integrated oncology platform to advance oncology pipelines using their exhaustive patient-derived xenograft (PDX) collection, innovative humanized tumor models and three dimensional ex vivo cultures that recapitulate the in vivo tumor microenvironment.

"Featured work will show data from novel models that enable precise evaluation of new cancer therapeutics, including bi-specific T-cell engagers (BiTEs), targeted cancer immunotherapies and combinatory immunotherapies," the statement said.

"The data presented will exhibit the utility of our clinically relevant solutions to identify critical biomarkers and improve preclinical evaluation of cancer therapies," said Crown Bioscience's vice-president of Translational Oncology, Dr. Henry Li.

Chief Business Officer, Laurie Heilmann said the work of the company's scientific team exemplifies Crown Bioscience's commitment to helping researchers solve global health challenges through continued innovation of scientific translational platform.

Delegates can request copies of the posters and learn more about Crown Bioscience's scientific translational platform at booth #3012.

Crown Bioscience is a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research.